Blockade of B7/CD28 in mixed lymphocyte reaction cultures results in the generation of alternatively activated macrophages, which suppress T-cell responses

Blood

Volumn 99, Issue 4, 2002, Pages 1465-1473

  Tzachanis, Dimitrios ^a   Berezovskaya, Alla ^a   Nadler, Lee M ^a   Boussiotis, Vassiliki A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BETA CHEMOKINE; CD23 ANTIGEN; CD28 ANTIGEN; FERRITIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; LYSOZYME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MANNOSE RECEPTOR; NEUTRALIZING ANTIBODY; SCAVENGER RECEPTOR;

ANTIGEN PRESENTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREACTIVITY; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MIXED LYMPHOCYTE REACTION; PHAGOCYTOSIS; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSPLANTATION TOLERANCE;

EID: 0037082456     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.4.1465     Document Type: Article

References (68)

1. Mechanisms of disease. Graft-versus-host disease
2. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program
3. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion
4. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice
5. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
6. Longterm acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
7. Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody
8. Transplantation of anergic histoincompatible bone marrow allografts
9. T cell clonal anergy
10. Prevention of T cell anergy by signaling through the γc chain of the IL-2 receptor
11. The role of B7-1/B7-2:CD28/CTLA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response
12. Development and heterogeneity of macrophages and their related cells through their differentiation pathways
13. Other functions, other genes: Alternative activation of antigen-presenting cells
14. Alternative versus classical activation of macrophages
15. Interleukin 4 potently enhances murine macrophage mannose receptor activity: A marker of alternative immunologic macrophage activation
16. Treatment of murine macrophages with interferon-gamma inhibits their ability to bind leishmania promastigotes
17. Interferon-gamma inhibits scavenger receptor expression and foam cell formation in human monocyte-derived macrophages
18. Identification of the integral membrane protein RM3/1 on human monocytes as a glucocorticold-inducible member of the scavenger receptor cysteine-rich family (CD163)
19. Human CD14 mediates recognition and phagocytosis of apoptotic cells
20. CD14-dependent clearance of apoptotic cells: Relevance to the immune system
21. Antagonistic and additive effects of IL-4 and interferon-gamma on human monocytes and macrophages: Effects on Fc receptors, HLA-D antigens and superoxide production
22. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: Competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype
23. Alternative macrophage activation-associated CC-chemockine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern
24. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells
25. Alternatively activated macrophages actively inhibit proliferation of peripheral blood lymphocytes and CD4+ T cells in vitro
26. Mouse placental macrophages have a decreased ability to present antigen
27. Phenotypic characterization of macrophages in human term placenta
28. MHC class 11 antigen-bearing dendritic cells in pulmonary tissues of the rat. Regulation of antigen presentation activity by endogenous macrophage population
29. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts
30. IL-10 producing T cells suppress immune responses in anergic tuberculosis patients
31. Activated human B lymphocytes express three CTLA4 binding counter-receptors which costimulate T cell activation
32. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages
33. B7-1 and B7-2 do not deliver identical costimulatory signals since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4
34. Suppression subtractive hybridization: A method for generating differentially regulated or tissue-specific cDNA probes and libraries
35. Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: A method to ameliorate graft-versus-host disease and extend the donor pool
36. Selective induction of B7/BB-1 on interferon-γ stimulated monocytes: A potential mechanism for amplification of T cell activation
37. Cloning of B7-2: A CTLA4 counter-receptor that costimulates human T cell proliferation
38. Split activity of interleukin-10 on antigen capture and antigen presentation by human dendritic cells: Definition of a maturation step
39. Interleukin-10 down-regulates MHC class II alphabeta peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling
40. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines
41. Blocking CD40-CD154 and CD80/CD86-CD28 interactions during primary allogeneic stimulation results in T cell anergy and high IL-10
42. Nitric oxide as a secretory product of mammalian cells
43. Sortilin/neurotensin receptor-3 binds and mediates degradation of lipoprotein lipase
44. Inhibition of in vitro differentiation of human monocytes to macrophages by lipopolysaccharides (LPS): Phenotypic and functional analysis
45. Characterization of mononuclear-phagocyte terminal maturation by mRNA phenotyping using a set of cloned cDNA probes
46. A CD4+ T-cell subset inhibits antigen-specific T cell responses and prevents colitis
47. CD28 costimulation can promote T cell survival by enhancing the expression of bcl-xL
48. The induction of tolerance by dendritic cells that have captured apoptotic cells
49. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
50. A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph codes
51. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/ paracrine mechanisms involving TGF-beta, PGE2, and PAF
52. Antiinflammatory effects of CD95 ligand (FasL)-induced apoptosis
53. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
54. PD-L2 is a second ligand for PD-I and inhibits T cell activation
55. Monocyte deactivation by interleukin 10 via inhibition of tyrosine kinase activity and the Ras signaling pathway
56. Improved survival and marrow engraftment of mice transplanted with bone marrow of GM-CSF-treated donors
57. Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation
58. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor
59. Transplantation of bone marrow as compared with peripheral blood cells from HLA-identical relatives with patients with hematologic cancers
60. Transplantation of filgrastim-mobilized peripheral blood stem cells from HLA-identical siblings or alternative family donors in patients with hematological malignancies: A prospective comparison on clinical outcome, immune reconstitution and hematopoietic chimerism
61. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype
62. Suppression of alloantigen-induced T cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells
63. Impaired induction of the CD28-responsive complex in granulocyte colony-stimulating factor mobilized CD45 T cells
64. Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: A mechanism for monocyte-mediated suppression of T-cell proliferation
65. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease
66. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells
67. - population
68. Mature monocytic cells enter tissues and engraft